• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Eli Lilly and Company Expands Lebanon, Indiana, Manufacturing Operations

Eli Lilly and Company plans to expand its manufacturing operations at the LEAP Research and Innovation District in Lebanon, Indiana. The $5.3 billion project is expected to create 200 jobs.

The investment will increase the company’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection. Initial operations are scheduled for the end of 2026.

“Lilly’s commitment to meeting the demand for our life-changing medicines goes beyond buildings and extends to improving education opportunities and upskilling a global workforce of the future,” said Edgardo Hernandez, executive vice president and president, Lilly Manufacturing Operations. “Academia is a critical partner to both industry and government as we work together to advance innovation in our state and communities around the globe.”

To support the project, the state will partner on infrastructure solutions – road improvements, water, electric and other utilities – as well as workforce development commitments and certain economic incentives tied to the company's achievement of investment and employment goals. The state's workforce development support includes the contribution of land, pending approval, for the construction of a learning and training center that will be part of the larger LEAP industrial development, along with a commitment to work with Lilly to raise capital for its completion.

"Lilly continues to play a transformational role in shaping Indiana's opportunity economy, and I couldn't be more proud about their pole position leadership in developing the LEAP Research and Innovation District in Lebanon, Indiana. Lilly has long been driving global innovation and economic growth that will be felt for decades here at home," noted Indiana Governor Eric J. Holcomb. "As an international company, headquartered in Indiana, Lilly had a world of options to consider before making this investment, and choosing Indiana once again reinforces the incredible environment we've cultivated and the talented workforce we have to carry Lilly's success forward. I can't wait to see the incredible benefits this investment leads to for patients around the world, knowing they were made in Indiana."

Since 2020, Lilly noted it has committed more than $16 billion to develop new manufacturing sites in the U.S. and Europe. New locations outside Indiana include; Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany.

Exclusive Research